Zilretta
Phase 3Small molecule
Pacira Pharmaceuticals, IncZilretta is one of 46 small molecule programs targeting Osteoarthritis. It is currently in Phase 3.
1
Indications
6
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
143 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Zilretta
Pacira Pharmaceuticals, IncPhase 3
Toradol
RochePreclinical
Cataflam
NovartisPreclinical
Bayer Aspirin
BayerPreclinical
Enbrel
IImmunex
Preclinical
Glucophage
EMD SeronoPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Catapres
Boehringer IngelheimPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Osteoarthritis3 trials
Adult1 trial
Injury1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zilretta. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company